Welcome to the Zenith Epigenetics Hub On AGORACOM

Zenith's Lead Pan Selective BET Inhibitor ZEN-3694 is Currently Being Evaluated in Phase 1 Prostate Cancer Clinical Trials


BREAKING:Monarques Gold Confirms Pit Constrained Resource on its Mckenzie Break

  • The mineral resource estimate for McKenzie Break was prepared for two scenarios:
    • Scenario 1: A pit constrained Indicated resource of 48,133 ounces and Inferred resource of 14,897 ounces, and an underground Indicated resource of 53,448 ounces and Inferred resource of 49,130 ounces, for a total of 165,608 ounces of gold.
    • Scenario 2: An underground Indicated resource of 85,059 ounces and Inferred resource of 58,373 ounces, for a total of 143,432 ounces of gold.
  • Monarques Gold now has a combined measured and indicated resource of more than 3 million ounces of gold

Monarquesgold hub large

Hub On AGORACOM / Read Release

Message: Zenith share issue

"This is to finance the next leg of the Phase I trial. This would be the breast cancer leg of the trial."

Good to hear this Tada. We don't want Gilead to get too far ahead with their GS-5829 BET inhibitor breast cancer trial

On a side note the Zenith website also listed immuno-oncology as a program of interest. An Endpoints News article yesterday highlighted how crowded this field is for immuno-oncology/checkpoint therapies, which presents a big challenge for finding cancer patients for these studies. 

It will be interesting to hear Zenith at the AGM discuss their plans going forward with immuno-oncology. And if they don't talk about it, someone should ask the question if they attend the AGM!


New Message
Please login to post a reply